WO2001014418A3 - PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI - Google Patents

PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI Download PDF

Info

Publication number
WO2001014418A3
WO2001014418A3 PCT/US2000/023161 US0023161W WO0114418A3 WO 2001014418 A3 WO2001014418 A3 WO 2001014418A3 US 0023161 W US0023161 W US 0023161W WO 0114418 A3 WO0114418 A3 WO 0114418A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cells
methods
apoptotic
pro
Prior art date
Application number
PCT/US2000/023161
Other languages
English (en)
Other versions
WO2001014418A2 (fr
Inventor
Loren J Field
Shih-Chong Tsai
Original Assignee
Advanced Res & Tech Inst
Loren J Field
Tsai Shih Chong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Res & Tech Inst, Loren J Field, Tsai Shih Chong filed Critical Advanced Res & Tech Inst
Priority to JP2001518747A priority Critical patent/JP2003520025A/ja
Priority to IL14828600A priority patent/IL148286A0/xx
Priority to EP00957721A priority patent/EP1212418A2/fr
Priority to AU69301/00A priority patent/AU6930100A/en
Priority to CA002383371A priority patent/CA2383371A1/fr
Publication of WO2001014418A2 publication Critical patent/WO2001014418A2/fr
Publication of WO2001014418A3 publication Critical patent/WO2001014418A3/fr
Priority to US10/080,943 priority patent/US20030073236A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des séquences nucléotidiques codant et régulant l'expression d'une protéine régulatoire du cycle cellulaire, appelée p193, et à des vecteurs recombinés et à des cellules hôtes contenant des séquences nucléotidiques codant et régulant l'expression de la séquence de cette protéine. Cette invention concerne également des procédés servant à modifier le cycle cellulaire d'une cellule en régulant la protéine p193 ou sa voie de passage. On obtient des procédés induisant l'apoptose dans des cellules, en accroissant le niveau d'une protéine p193 pro-apoptotique dans ces cellules. On obtient des procédés supprimant l'apoptose dans des cellules ou accroissant le potentiel prolifératif de cellules, en réduisant le niveau de la protéine p193 pro-apoptotique dans ces cellules et/ou en interférant avec la voie de transduction du signal de la protéine p193 native, par exemple en utilisant une protéine p193 ayant une mutation négative dominante.
PCT/US2000/023161 1999-08-23 2000-08-23 PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI WO2001014418A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001518747A JP2003520025A (ja) 1999-08-23 2000-08-23 ｐ１９３タンパク質、並びにその核酸及び使用
IL14828600A IL148286A0 (en) 1999-08-23 2000-08-23 P193 proteins and nucleic acids, methods for the preparation thereof and pharmaceutical compositions containing the same
EP00957721A EP1212418A2 (fr) 1999-08-23 2000-08-23 PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI
AU69301/00A AU6930100A (en) 1999-08-23 2000-08-23 P193 proteins and nucleic acids, and uses thereof
CA002383371A CA2383371A1 (fr) 1999-08-23 2000-08-23 Proteines p193 et acides nucleiques, et utilisations de ceux-ci
US10/080,943 US20030073236A1 (en) 1999-08-23 2002-02-22 p193 proteins and nucleic acids, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15026699P 1999-08-23 1999-08-23
US60/150,266 1999-08-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/080,943 Continuation US20030073236A1 (en) 1999-08-23 2002-02-22 p193 proteins and nucleic acids, and uses thereof

Publications (2)

Publication Number Publication Date
WO2001014418A2 WO2001014418A2 (fr) 2001-03-01
WO2001014418A3 true WO2001014418A3 (fr) 2002-02-14

Family

ID=22533769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023161 WO2001014418A2 (fr) 1999-08-23 2000-08-23 PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI

Country Status (6)

Country Link
EP (1) EP1212418A2 (fr)
JP (1) JP2003520025A (fr)
AU (1) AU6930100A (fr)
CA (1) CA2383371A1 (fr)
IL (1) IL148286A0 (fr)
WO (1) WO2001014418A2 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 3 November 1994 (1994-11-03), NOMURA N. ET AL.: "Human mRNA for KIAA0076 gene, complete cds.", XP002175737, retrieved from EBI Database accession no. D38548 *
TSAI SHIH-CHONG ET AL: "Simian virus 40 large T antigen binds a novel Bcl-2 homology domain 3-containing proapoptosis protein in the cytoplasm.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 5, 4 February 2000 (2000-02-04), pages 3239 - 3246, XP002175735, ISSN: 0021-9258 *
TSAI, SHIH-CHONG: "TUMOR SUPPRESSOR PATHWAY IN MYOCARDIUM (RAD50, PHOSPHOPROTEINS)", February 1999, DISSERTATION ABSTRACTS INTERNATIONAL AAD99-19502, MICHIGAN, XP002175736 *

Also Published As

Publication number Publication date
EP1212418A2 (fr) 2002-06-12
JP2003520025A (ja) 2003-07-02
WO2001014418A2 (fr) 2001-03-01
IL148286A0 (en) 2002-09-12
AU6930100A (en) 2001-03-19
CA2383371A1 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
EP1798239A3 (fr) Récepteurs de protéine G-couplés et utilisations correspondantes
CA2323086A1 (fr) Regulation de l'expression genique endogene dans des cellules au moyen de proteines a doigts de zinc
EP1757689A3 (fr) Famille de gènes mammaliens de protéines inhibant l'apoptose (iap), amorces, sondes et procédés de détection
ATE384798T1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
AU7599500A (en) Novel gl50 molecules and uses therefor
ATE286136T1 (de) Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
HUP0001650A2 (hu) Javított expressziós vektorok
NZ509633A (en) A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
WO2002006457A3 (fr) Genes de lipase
WO1998056927A3 (fr) Acides nucleiques codant des polypeptides a fonction protease
MX9801864A (es) Materiales y metodos con relacion a la union y presentacion de substancias sobre superficies de celulas.
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
EP0804609A4 (fr) NOUVEAUX GENES DE REPONSE p53
WO2000078922A3 (fr) Promoteurs inductibles par acide pour l'expression genetique
HK1158529A1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
AU3802595A (en) Tripeptidyl aminopeptidase
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
WO2002036627A3 (fr) Interferons, utilisations et compositions associees
WO2003062453A3 (fr) Acides nucleiques et proteines associes a la polykystose renale
HUP9900750A2 (hu) Gén kifejezésére szolgáló promóterek
WO2001014418A3 (fr) PROTEINES p193 ET ACIDES NUCLEIQUES, ET UTILISATIONS DE CEUX-CI
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383371

Country of ref document: CA

Ref document number: 148286

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10080943

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/291/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 69301/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000957721

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000957721

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000957721

Country of ref document: EP